Optimize mAb Process Development To Reach Your Goals Quickly

The rapid growth of monoclonal antibodies and their variants, including bispecific antibodies and antibody drug conjugates, to treat cancer, autoimmune diseases, and other chronic conditions, has increased the need for accelerated and risk averse process development. En route to delivering these groundbreaking therapies to patients, early-optimization is critical. The strategies for ensuring high productivity mAb manufacturing include stable cell line development, optimized media, diverse feed strategies, and high throughput screening techniques to accelerate both upstream and downstream processes.

By strategically selecting the right tools and approaches from the outset, mAb developers can significantly reduce timelines, enhance yields, and ultimately, bring life-changing treatments to patients with greater speed and efficacy. Download the full article to explore the different strategies and technologies available to help accelerate your mAb development and maintain high quality along the way.